Rein Therapeutics
RNTX
23 hedge funds and large institutions have $4.03M invested in Rein Therapeutics in 2018 Q3 according to their latest regulatory filings, with 9 funds opening new positions, 10 increasing their positions, 2 reducing their positions, and 6 closing their positions.
400% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 2
50% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 6
15% more funds holding
Funds holding: 20 → 23 (+3)
0.33% more ownership
Funds ownership: 0.3% → 0.64% (+0.33%)
17% less capital invested
Capital invested by funds: $4.84M → $4.03M (-$814K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SLF
Sun Life Financial
Toronto,
Ontario, Canada
|
+$1.69M |
| 2 |
Morgan Stanley
New York
|
+$1.37M |
| 3 |
PL
Parkwood LLC
Cleveland,
Ohio
|
+$182K |
| 4 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$168K |
| 5 |
Renaissance Technologies
New York
|
+$167K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
-$813K |
| 2 |
PP
Paloma Partners
Greenwich,
Connecticut
|
-$140K |
| 3 |
Millennium Management
New York
|
-$134K |
| 4 |
Norges Bank
Oslo,
Norway
|
-$96K |
| 5 |
LP
LMR Partners
London,
United Kingdom
|
-$71K |
RNTX Hedge Fund Activity: Q3 2018 in Review
23 of the 4,375 institutional investors tracked by Wall St. Rank reported a position in Rein Therapeutics (RNTX) for Q3 2018, worth a combined $4.03M — down 17% from $4.84M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new RNTX positions and 6 closed out — a net gain of 3 holders — while 10 added to existing stakes and 2 trimmed.
The largest buyer was Sun Life Financial, opening a new position worth an estimated $1.69M. The largest seller was Candriam SCA, exiting entirely with an estimated $813K sold.
- 23 institutional investors held Rein Therapeutics (RNTX) as of Q3 2018, up from 20 in Q2 2018.
- Funds reported $4.03M of Rein Therapeutics stock for Q3 2018, down 17% quarter-over-quarter.
- 9 funds opened new Rein Therapeutics positions in Q3 2018 and 6 closed out, a net change of +3 holders.
- The largest Rein Therapeutics buyer in Q3 2018 was Sun Life Financial, an estimated $1.69M added.
- The largest Rein Therapeutics seller in Q3 2018 was Candriam SCA, an estimated $813K sold.
Based on aggregated 13F filings for Q3 2018.